Evaluation of Skin Quality Improvement When Hyper-Diluted OnabotulinumtoxinA (Botox®, Botox® Cosmetic /BTXa/) is Injected Into The Superficial Dermis of the Mid-Face
Overview
- Phase
- Phase 2
- Intervention
- Topical anesthesia
- Conditions
- Skin Quality
- Sponsor
- Steve Yoelin M.D. Medical Associates, Inc.
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- Percent Improvement in Skin Quality
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this study is to comprehensively investigate and objectively demonstrate the effectiveness of hyperdiltue Botox® Cosmetic in improving overall skin quality, more specifically evenness of skin tone, reduction of pore size and improvement in the appearance of preexisting skin scars.
Detailed Description
The purpose of this study is to comprehensively investigate and objectively demonstrate the effectiveness of hyperdiltue Botox® Cosmetic in improving overall skin quality, more specifically evenness of skin tone, reduction of pore size and improvement in the appearance of preexisting skin scars. The ability of hyperdilute Botox® Cosmetic to improve overall skin quality is likely optimized when it is injected uniformly in hyper-diluted small aliquots in order to "saturate" the dermis. We propose to prepare Botox® Cosmetic in a manner that is approximately 4 times more dilute compared to the typical Botox® Cosmetic preparation. A 4x4 centimeter area located in the mid-cheek adjacent to the nose will be injected with hyperdilute Botox® Cosmetic. Botox® Cosmetic is not FDA-approved for this use. A maximum of 15 subjects will participate in this study, all of whom will receive injections of Botox® Cosmetic during the course of this study. This study is a randomized, placebo-controlled, and double-masked study. This means neither the study doctor nor participant know the experimental agent (e.g., 0.9% saline solution and hyperdiluted Botox® Cosmetic) injected on each side of the patients' faces. The study will last for a total of 75 days. Evaluation of the study is based on the analysis of photographic images obtained during the study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Ability to follow study instructions and likely to complete all required visits
- •Written consent has been obtained
- •Written authorization for "Use and Release of Health and Research Study Information" has been obtained
- •Subjects who are Fitzpatrick Skin Types II-IV
Exclusion Criteria
- •Subjects must be Onabotulinum Toxin Type A naive; if subject has had Onabotulinum Toxin Type A administered in the face in the previous 12 months they are excluded
- •Subjects must be dermal filler naïve in the lateral canthal region and midface regions
- •Subjects must be energy or light device naïve
- •Subjects must have average or below-average lifetime sun exposure
- •Subjects must be free of inflammatory skin disease(s)
Arms & Interventions
Group B
Group B will be treated with 0.9% saline solution on day 1 and on day 30 they will be treated with Hyper-Diluted Botox.
Intervention: Topical anesthesia
Group B
Group B will be treated with 0.9% saline solution on day 1 and on day 30 they will be treated with Hyper-Diluted Botox.
Intervention: 0.9% saline solution
Group A
Group A will be treated with Hyper-Diluted Botox on day 1 and on day 30 they will be treated with 0.9% saline solution.
Intervention: Hyper-Diluted Botox
Group A
Group A will be treated with Hyper-Diluted Botox on day 1 and on day 30 they will be treated with 0.9% saline solution.
Intervention: Topical anesthesia
Group A
Group A will be treated with Hyper-Diluted Botox on day 1 and on day 30 they will be treated with 0.9% saline solution.
Intervention: 0.9% saline solution
Group B
Group B will be treated with 0.9% saline solution on day 1 and on day 30 they will be treated with Hyper-Diluted Botox.
Intervention: Hyper-Diluted Botox
Outcomes
Primary Outcomes
Percent Improvement in Skin Quality
Time Frame: Entire duration of the study (Day 1-Day 135)
An evaluation of the percent improvement in skin quality when the "Onabotulinum Toxin Type A" treated side of face is compared to the "placebo" treated side of the face. Good skin quality is defined as small pore size, evenness of skin texture, evenness of skin tone, minimal presence of wrinkles, and minimal presence of scars. We will measure improvement primarily by image analysis of the photos taken during each visit using the Canfield Scientific camera (or the Allergan provided alternative).
Secondary Outcomes
- Patient and Investigator Reported Outcomes(Entire duration of the study (Day 1-Day 135))